GLIMPSES OF CSIR-CDRI AND INDUSTRIES/ACADEMIA COLLABORATION

CSIR-Central Drug Research Institute, Lucknow
Licensing Agreement executed with M/s GenetoProtein Pvt. Ltd., Lucknow on 16/02/2022 w.r.t. “A Nucleic Acid Staining Dye for Biomedical Applications.”
फास्ट न्यूज
सीडीआरआई ने जीटीपी को दिया टेक्नॉलॉजी लाइसेंस

एनबीटी, लखनऊ: सीडीआरआई ने जीन टू प्रोटीन (जीटीपी) प्राइवेट लिमिटेड को न्यूक्लिक एसिड स्टेनिंग डाई ग्रीनआर की प्रौद्योगिकी का लाइसेंस दिया है। वरिष्ठ प्रशासन वैज्ञानिक डॉ. अतुल गोयल ने संस्थान के बायोटेक डेस्क प्राइवेट लिमिटेड हैदराबाद के साथ मिलकर तकनीकी विकसित की है। सीडीआरआई के निदेशक डॉ. श्रीनिवास रेड्डी ने बताया कि न्यूक्लिक एसिड स्टेनिंग डाई मेक-इन-इंडिया उत्पाद काफी किफायदी और सुरक्षित है।

CSIR-Central Drug Research Institute, Lucknow
CSIR-CDRI transferred the technology of "A Nucleic Acid Staining Dye (Green R)" to M/s. Geneto Protein Pvt. Ltd., Lucknow during 10-11 May - 2022 for Biomedical Applications.

CSIR-Central Drug Research Institute, Lucknow
CSIR-CDRI and Aveta Biomics, USA Announce License to Aveta Biomics for the Development and Commercialization of First-in-Class Bone Health Drugs
अमेरिका में भी मिलेगी CDRI की दवा

अस्थि स्वास्थ्य दवा को लेकर सीडीआरआई व अमेरिकी कंपनी के बीच करार

लखनऊ (एसएएसबी)। हर्षु की स्वस्थ रखने और मज़बूत रहने के लिए देरी-देरी आयुर्विज्ञान सुसंधान में सहायता (सीडीआरआई), लखनऊ द्वारा की तैयार की प्रथम रूप से अमेरिका के लोगों को पहली उपलब्धि हो सकेगी। इस तरीके के विकास और व्यापकताप्रदर्शन के लिए सीडीआरआई और अमेरिका की एकता वायोजिक्स (यॉर्कटन) कंपनी के बीच करार हुआ है तथा सीडीआरआई ने अमेरिका की एक मेडिकल सार्वजनिक को तालिका देने की अनुमति दी है। सीडीआरआई के कंपनी की तालिका मिलने के बाद सीडीआरआई द्वारा कार्यक्रमों में तैयार की गई उपलब्धि वनिल बन नियुक्त हो सकेगी।

सीडीआरआई के एडिभन नेटली विद्युत के वर, एडिथ विद्युत के वर कहा कि विधान की पत्रियों में बारेंचर्चार कुर्मेड तत्त्व जाना जाता है, जो हर्षु के कारण संजीवित से कम नहीं है। इस तरह की खास प्रक्रिया से भर्तर के बाद दवा तैयार की गई है। भारत में कर्त 2017 में शीर्ष की पत्रि। द्वारा दवा टेक्नोलॉजी की तैयारी जा रही है। अब अमेरिका की कंपनी की तालिका दिया गया है। सीडीआरआई द्वारा, दवा तैयार कर रही करों के बाल्क आगे श्रेय देने करती है।

भारत में 50 मिलियन महिलाएं औस्ट्रोपोरोसिस के बीडिट दवा। कहती हैं उनके लिए, पुष्पवोध व महिलाओं की हंसरु लकड़ी थी जो उन्हें तालाब तरह की हंसियों की कामबंदी से जाना जाता है। इससे स्वस्थता फारो या अन्धविराज (आयोजित स्वस्थता), भारत के अनुसार 50 मिलियन भारतीय महिलाओं की अंगिनी कल्पना से पीड़ित थी। दुनिया भर में हर साल में से एक महिला और 50 बालक से आक्रामक उप के दर पुष्पवोध में से एक का अंगिने काल्पनिक फैक्टर को संबंधित होती है। अनेकों अमेरिका में 50 बालक से आक्रामक आयुक्त के अनुसार 10 मिलियन लोगों की अंगिनी कल्पना है और संकुलक राज्य अमेरिका में हर साल में से एक महिला अपने जीवनकाल में एक बाल नज़र से अवकाश पहुँच होती है। अमेरिका में 45 मिलियन से आक्रामक लोगों में हंसरु के प्रमाण कम है, किसानों ने अंगिनी का उपयोग कई बार जड़ बनाया है। विशेष रूप से वर्ष 2010 में 178 मिलियन नए बालक और बालक जाने के अंगिनी के 455 मिलियन मामले रिकॉर्ड हैं थे।

CSIR-Central Drug Research Institute, Lucknow
CDRI bone health drug to be developed in US

Lucknow: CSIR-Central Drug Research Institute’s osteoporosis drug launched in 2015 will be the first drug of the institute to be used by patients in the United States. CDRI has given the license of its patented drug Caviunin Scaffold to Aveta Biomics which is a leader in developing the next generation of botanical drugs for its development and commercialization.

Caviunin Scaffold has broad applications for bone health that includes its efficacy in treating osteoporosis, fracture healing, osteoarthritis and other endocrinological conditions.

The drug has dual benefits as it helps both in bone formation and also bone resorption (breakdown of tissues in bones).

“Scaffold has a targeted action that prevents bone breakdown, stimulates new bone formation and reduces bone clinical markers. The license to Aveta Biomics is a testament to the calibre of our innovative science and demonstrates the value of the strong research,” said principal scientist Ritu Trivedi, who led the osteoporosis drug research.

CSIR-CDRI director Prof Tapas Kundu said, “We joined hands with Aveta Biomics given their track record of obtaining four clinical investigational new drugs (INDs) applications of their botanical drugs and for several cancer indications from the US Food and Drug Administration. We expect, therefore, translation of CDRI’s research into real drugs for people living with bone-related conditions not only in India but abroad also.”

“Osteoporosis is a chronic condition requiring lifelong treatment. Approved treatment duration of currently available drugs ranges from one to five years (depending on the drug) due to waning efficacy and increased risk of adverse events. Caviunin-based therapeutic has a huge potential to change the standard of care for osteoporosis,” said CEO of Aveta Biomics Parag G. Mehta.
अगले दो मह तक वाजार में मिलेगी स्वदेशी डाई

लखनऊ: जीव विज्ञान संस्करण से श्रीमान बीमा बीमारियों में समय पर (डाइआक्साइड न्यूजिलक एसिड) और (আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ ই আ डाइआक्साइड न्यूजिलक एसिड) का प्रयोग में उपयोग होने वाली बाई पर सीडीआरआई के विज्ञानियों की सफलता एक कदम और आगे बढ़ गई है। प्रयोगाधारा के उपयोग के लिए आगे दो मह में यह स्वदेशी बाई बाजार में उपलब्ध होगी। सीडीआरआई के निदेशक एड़ीशन श्रीनिवास मिन्दुः के अनुसार, भारतीय शोधकर्ताओं को इस नवाचार से विदेशी महंगी बाई पर निर्भरता कम होगी।

CSIR-Central Drug Research Institute, Lucknow
CSIR-CDRI technology of “An Industrially Viable Process of an Orally Active Investigational New Drug S007-1500 for Fracture Healing” transferred to M/s Troikaa Pharmaceuticals Limited, Ahmedabad to 14-16 February, 2022
सीएसआरआईआर-सीडीआईआर के 71वें वार्षिक दिवस पर नई दा की घोषणा दूसरी हड्डियों के लिए टैबलेट जल्द

राहत

सीएसआरआईआर-सीडीआईआर के 71वें वार्षिक दिवस पर नई दा की घोषणा दूसरी हड्डियों के लिए टैबलेट जल्द

राहत

सीएसआरआईआर-सीडीआईआर के 71वें वार्षिक दिवस पर नई दा की घोषणा दूसरी हड्डियों के लिए टैबलेट जल्द

राहत

सीएसआरआईआर-सीडीआईआर के 71वें वार्षिक दिवस पर नई दा की घोषणा दूसरी हड्डियों के लिए टैबलेट जल्द

राहत

सीएसआरआईआर-सीडीआईआर के 71वें वार्षिक दिवस पर नई दा की घोषणा दूसरी हड्डियों के लिए टैबलेट जल्द

राहत

सीएसआरआईआर-सीडीआईआर के 71वें वार्षिक दिवस पर नई दा की घोषणा दूसरी हड्डियों के लिए टैबलेट जल्द

राहत

सीएसआरआईआर-सीडीआईआर के 71वें वार्षिक दिवस पर नई दा की घोषणा दूसरी हड्डियों के लिए टैबलेट जल्द
Licensing Agreement signed with M/s MARC Laboratories Pvt. Ltd., Lucknow on 10 June 2021 w.r.t. CDRI Antiplatelet Compound S007-867

CSIR-Central Drug Research Institute, Lucknow
Demonstration of Know-How process technology of “A Novel Small Molecule Antiplatelet Compound S007-867” during 13-15 December, 2021

CSIR-Central Drug Research Institute, Lucknow
CDRI transfers tech for drug of heart attack, stroke

CDRI, committed to support the pharma cluster in Uttar Pradesh, has tied up with UP-based Marc Laboratories Pvt Ltd, a young progressive enterprise with an operating base in 13 other states. It had earlier signed an agreement for the development of a synthetic compound S-007-867.

"This may be helpful in treating the patient population of coronary and cerebral artery diseases. The institute has recently obtained the permission to initiate the phase-I clinical trials for the drug," CDRI spokesperson Sanjeev Yadav said.

Director TK Kundu said it is a great moment for CSIR-CDRI, the premiere drug development research institute of the country, as it has transferred the technology for the synthesis of the compound successfully to Marc Laboratories Ltd. "It will allow Marc Laboratories to scale up the methodology for production of the compound under cGMP conditions. It will help them initiate the phase-I clinical trials with the drug to check its safety and efficacy in human subjects," he said.

"I am optimistic that this compound will reach the market in quick time for the benefit of humanity. The industry-academia partnership will be very beneficial for development of the pharma cluster in UP and will open up new avenues for 'Made in India' and indigenous affordable drugs," he added.

Chairman of Marc Laboratories Prem Kishore said, "Marc's association with CSIR-CDRI will be beneficial to both parties and they will be working hard to take the novel compound forward and complete all regulatory requirements so that it reaches the market at the earliest.''

The technology for the preparation of the compound S007-867 was demonstrated by Sonuy Batra and Anil Ksh in the team of Marc Laboratories headed by plant manager Avirsh Sinastava.

The CDRI spokesperson said, "Arterial thrombosis is an acute complication that develops on the chronic lesions of atherosclerosis, leading to heart attack and stroke. "Therefore,
संबंधित व्यक्तियों का उचित सम्मान करने के लिए पूरी तुलना की जाती है। ज्ञातियों के सम्मान में इस्तेमाल किए गए नाम और उल्लेख अनिवार्य हैं। इस विषय की अन्य जानकारी के माध्यम से अनुसरण की जाएगी।
Transfer of technology to M/s Biotech Desk Pvt. Ltd. (BDPL), Hyderabad on 17-02-2021.

CSIR-Central Drug Research Institute, Lucknow
सीडीआरआई ने कोविड जांच के लिए बनाई स्वेदशी किट
अनुमति के बाद दो महीने में शुरू हो जाएगी '��ीफ्लोर कोविड' किट से जांच

भारत के कोविड जान के लिए बैंक और व्यक्तियों के क्षेत्र में भाग लेने से पहले, सीडीआरआई के अध्यक्ष मिश्रित (आदिकी) ने कहा कि कोरोना के लिए कोई नया कीट बनाने के लिए जांच करने की जांच निर्देशित कर दी गई है। इसके लिए अभी तक इस देश में जांच की जा रही है।

संस्थान के 70 वर्षों में दिनांकित किट का निर्माता बना लेना होगा। संस्थान के निदेशक जी.एम. मुद्रा को कहा है कि संस्थान के लिए यह लिंक का कार्य है कि संस्थान से लेकर सीडीआरआई के कोविड जांच के लिए स्वेदशी किट का निर्माता बनने के लिए इसका जारी किया जाए।

30 प्रतिशत सतीश होगी जांच

संस्थान ने दिए दवाओं के सुरक्षित विकास

संस्थान भारत व पश्चिम अफ्रीका के लिए सुरक्षित विकास दवाओं के लिए रोकता है जो संस्थान के रूप में लाल रंग में दर्ज किए हों।

CSIR-Central Drug Research Institute, Lucknow
CDRI tech to make RT PCR cheaper

TOWARDS SELF-RELIANCE

The reagent used in RT PCR test kit for Covid-19 is imported from foreign countries. Due to this, the cost of the test is high. Now, the reagent has been indigenously developed by CSIR-CDRI.

The tech transfer happened on CDRI’s annual day on Wednesday.

The institute has transferred the technology, developed after a year of research, to a Hyderabad-based firm.

To support hosp, industry in R&D

Synergy: The Central Drug Research Institute (CDRI) has established a Common Research and Technology Development Hub (CRTDH) to extend support to hospitals for clinical trials and to pharma industry, NSMEs and academicians for conducting advanced research.

CRTDH was inaugurated during the 70th annual day celebration of the institute on Wednesday.

“CRTDH is not only for scientists but for institutions conducting advanced research in the field of drug discovery. CDRI will not only provide infrastructure support like high-end laboratories and equipment but also the expertise of our scientists,” said CDRI spokesperson Sanjeev Yadav.

Lucknow: Considered the most reliable method to confirm Covid-19 infection, the RT PCR test will cost much lesser soon. Besides, it will give results in a few hours instead of taking a day as it does now. The reverse transcription polymerase chain reaction (RT PCR) test detects the virus in a human cell using a reagent. The reagent is imported from foreign countries due to which the cost of the test is high.

Now the reagent has been indigenously developed by CSIR-CDRI Central Drug Research Institute (CDRI) after a year’s work. The reagents bind with the viral genome to indicate whether a person is infected with a virus. With CSIR-CDRI developing the technology and transferring it to Hyderabad-based M/s Biotech Desk Pvt Ltd, the test will become cheaper and also give results quicker.

The tech transfer happened during CSIR-CDRI’s 70th annual day celebrations held on Wednesday.

Senior principal scientist Atul Goel and his team made the fluorescent dyes and quenchers (reagents). “The team began working on this technology in July, when the cost of a Covid test was around Rs 4,000 per sample. RT PCR is the most robust and reliable method of testing for Covid-19. It utilizes the costly imported TaqMan probe (reagent),” said Goel.

“CDRI’s dyes and quenchers will reduce the dependency on supply of reagents and kits from foreign manufacturers. Our larger goal is capacity building for India to make India self-reliant,” he added.

“This is also a step on the path of ‘Atmanirbhar Bharat,”’ said CDRI spokesperson Sanjeev Yadav.

CSIR-Central Drug Research Institute, Lucknow
Licensing Agreement executed with Medizest Pharmaceuticals Pvt. Ltd., Goa, w.r.t. "Process for the preparation of Umifenovir" on 24/04/2020

CSIR-Central Drug Research Institute, Lucknow
सीडीआरआई का दावा, बना ली है कोरोना की स्वदेशी दवा

उमीफेनोविर से वायरल लोड 5 दिन में खत्म करने का दावा, हलके एवं लक्षणहीन रोगियों में प्रभावी, उच्च जोखिम वालों के लिए भी उपयोगी

केजी, एयर एवं लोहिया से सहयोग से तीसरे चरण का क्लिनिकल ट्रायल सफल

देश वैदिक पर भी हो सकती है कार्य

Umifenovir cures Covid in 5 days: CDRI director

Coronavirus becomes zero in five days with Umifenovir, the drug developed by the Central Drug Research Institute (CDRI), and the dosage is two tablets a day, director Prof TK Kundu said while addressing mediapersons on Tuesday.

Sharing the findings of the Umifenovir trials conducted at three institutes of the city, Prof Kundu said they are waiting for the green signal from the Drug Controller of India after which it would hit the market within two months.

“We have seen that Umifenovir is working fantastically against Covid and the coronaviruses become zero without any adverse symptoms in five days. None of the patients have gone from mild to severe during the trials. The drug is going to be the cheapest as compared to other drugs available in the market today,” he said.

About the challenging times which they faced while developing the drug, he said: “Umifenovir (Arbidol) was selected from among 16 suggested candidates of CSIR upon looking into the feasibility of synthesis using locally available chemicals at the peak of pandemics. Locking into the back-ground and looking into the possibility of synthesis, we decided to go for Umifenovir. This drug is being used for the last 20 years in Russia and China for common cold, and we decided to take this forward for anti-Covid drug repurposing. We decided to start with the synthesis with whatever we had in our laboratories at a time when no vehicles were plying due to lockdown.”

He said that nearly four labs started synthesizing this drug and in record time, they finished the synthesis on the campus.

“In the meantime, we got in touch with a company in Goa which was interested in this and through video-conferencing, we showed step-by-step chemical reactions. The technology was transferred to the company online and we prepared the documents for what we had to the Drug Controller General of India and got the approval for phase-3 clinical trials,” he said.

He added that the dosage used in the study had not been tested earlier against SARS-CoV-2 and was in the process of being patented by CDRI.

Dr Himanshu Reddy and Dr Virendra Atam, the project investigators at KGMU, said that the faster recovery of Covid patients would reduce virus shedding and consequent spread of the infection to others. Dr MMA Faridi of ERA said that Umifenovir could be prescribed for pregnant women and children too, when approved. Dr Vilrama Singh of RMIMS suggested that it was Umifenovir was safe and had significant efficacy in mild asymptomatic patients, it could be useful as a prophylactic for high-risk patients.
Licensing Agreement signed with M/s. Lumen Marketing Company, Chennai on 17 February 2019 w.r.t. CSIR-CDRI plant product N-012-0001 for the early management of Benign Prostatic Hyperplasia (BPH)

CSIR-Central Drug Research Institute, Lucknow
Demonstration of Know-How process technology for the preparation of the CSIR-CDRI plant product N-012-0001 for the early management of Benign Prostatic Hyperplasia (BPH)
CDRI transfers tech for enlarged prostate mgmt

PIONEER NEWS SERVICE • LUCKNOW

Central Drug Research Institute (CDRI) transferred the technology of a plant-based nutraceutical product which has no steroids and helps in the management of enlarged prostate, a problem commonly faced by men in the age group of 50. The transfer of technology took place on the occasion of its Foundation Day on Sunday.

Scientist Sanjeev Yadav said CDRI signed a licensing agreement with Lumen Marketing Company, Chennai. CDRI director Tapas Kumar Kundu said the company entered into the agreement with the institute to market this nutraceutical product. Yadav said enlarged prostate was the most common problem of elders and ranks among top 10 most commonly diagnosed conditions in men above 50 years of age.

Pathologically, benign prostatic hyperplasia (BPH) is a condition in which non-cancerous growth of the prostate gland makes urination quite frequent and uncomfortable.

Enlarged prostate is the most common problem of elders and ranks among top 10 most commonly diagnosed conditions in men above 50 years of age.

“The prevalence of this disease is age-dependent, with initial development usually after 40 years of age. More than half of men in their 60s and up to 90 per cent of men in their 70’s and 80’s have some symptoms of BPH. This plant-based nutraceutical product is non-steroidal and safe,” he said.

The salient features of the product include its development from a single Ayurvedic medicinal plant and specific bioactive marker which has been identified to regulate the quality control of the developed nutraceutical product. The medicinal plant material is abundant in wild and grown commercially.

“The plant material is easily renewable and a cost-effective process has been developed to make bioactive enriched fraction at CDRI. This plant material is also specified in schedule IV list of FSSAI regulations to use it as a nutraceutical product,” Yadav said.
फार्मा स्टार्टअप को बढ़ावा देकर ही चौथी ओधियोगिक क्रांति संभव

अमर उजाला राजधानी/अर्ध

सीधासाहेब के वारिष्ठ समारोह में एकत्रित के गीती ने फार्मा स्टार्टअप पर दिया जोर।

इनको भी दिए गए अवार्ड

(वह इंडियन पर संदर्भित विभाग आयोग-2015, इंडियन पर संदर्भित विभाग आयोग-2019 अवार्ड के लिए नवीकरण इंडियन पर संदर्भित विभाग आयोग-2019 अवार्ड रेपलन) राहुल अधिग्रहण के दौरान समूह के नए संबंधित वायुमार्ग के लिए नवीकरण की गई गई।

इसके अलावा गीती दलितक लिखित 'स्टार्टअप-2019' के लिए आयोग इंडियन पर संदर्भित विभाग आयोग-2019 के लिए नवीकरण इंडियन पर संदर्भित विभाग आयोग-2019 अवार्ड लाभदायक नवीकरण इंडियन पर संदर्भित विभाग आयोग-2019 अवार्ड लाभदायक नवीकरण इंडियन पर संदर्भित विभाग आयोग-2019 अवार्ड लाभदायक नवीकरण इंडियन पर संदर्भित विभाग आयोग-2019 अवार्ड लाभदायक

CSIR-Central Drug Research Institute, Lucknow
Licensing Agreement signed with M/s Pharanza Hebal Pvt. Ltd., Gujarat on 17 February 2018 w.r.t. Standardized Fraction 219C002 for Treatment of Glucorticoid-induced Osteoporosis

CSIR-Central Drug Research Institute, Lucknow
Demonstration of Know-How process technology for the Bioactive extract and formulation of CDRI 219-C002 from the terrestrial plant Cassia occidentalis for bone regeneration and mitigation of corticosteroid-induced osteoporosis,*

CSIR-Central Drug Research Institute, Lucknow
Signing of Technology Transfer Document w.r.t. “CDRI product CDR2492/C003 – a standardized formulation for the management of osteoarthritis”

CSIR-Central Drug Research Institute, Lucknow
Licensing Agreement signed with M/s. Pharmanza Hebal Pvt. Ltd., on 31 July 2017 w.r.t. CDRI product CDR2492/C003 – a standardized formulation for the management of osteoarthritis

CSIR-Central Drug Research Institute, Lucknow
Joint Fresh launched for marketing on 13 March 2018 for the management of osteoarthritis

CSIR-Central Drug Research Institute, Lucknow
CDRI launches nutraceutical to prevent osteoarthritis

Director, CSIR-CDRI, Alok Dhawan launched a nutraceutical with a special dietary ingredient from palak (spinach) to prevent osteoarthritis. "Nutraceuticals can be considered non-specific biological therapies used to promote general well-being, control symptoms and prevent disease processes," said media incharge of CDRI Sanjeev Yadav.

He said that the product would be available as ‘Joint Fresh’ in the market after a scientific validation to maintain by CSIR-CDRI. It had been launched with Pharmanza Herbs Pvt Ltd and its ‘marketing partner Aeran Lab (India) Pvt Ltd. “This nutraceutical has extra health benefits for osteoarthritic joints in addition to the basic nutritional value found in Spinacea oleracea (palak). The product will now be available in the market at medical stores and online at longlivelives.com. The nano formulation was licensed to Pharmanza Pvt Ltd on July 31, 2017. Executive director, Aeran Lab (India) Pvt Ltd, Sanjeev Agarwal and a team of researchers were present on the occasion,” he added. The team of researchers behind this success story included scientists Ritu Trivedi, Prabhat Ranjan Mishra, Rakesh Maurya, SK Rath, Brijesh Kumar and PK Shukla. The research students, who were a part of this project, were Dharmendra Choudhary, Priyanka Kothari, Ashish Tripathi, Sudhir, Naresh Mittapelly, Kapil Dev, Gitu Pandey, Naseer Ahmad and Sulekha Adhikary, and among the supporting staff were SC Tiwari and GK Nagar.

Yadav said that the CSIR-CDRI had identified Spinacea oleracea (desi palak) for the prevention of osteoarthritis and degeneration of cartilages. "It imparts no toxicity and is effective at lower doses with nano formulation. Presently no oral drug was available to cure osteoarthritis, he said.

He said: ‘Nutraceutical’ stands for two words – ‘nutrient’ (a nourishing food component) and ‘pharmaceutical’ (a medical drug) or it means that ‘let food be your medicine.’ Talking about osteoarthritis, he said that it was a condition which affected the joints. “The surfaces within joints get damaged so they do not operate as smoothly. It affects mainly the weight-bearing joints such as hips and knees and causes physical disability. Both men and women are affected by osteoarthritis. Only symptomatic treatments are available with pain killers like ibuprofen and Naproxen. These drugs on long term use show liver and renal toxicity and also have a negative impact on the gastric and cardiac status of the patients,” he added.
The Lab scale technology of CDR2492/C003 – A standardized formulation for the management of osteoarthritis demonstrated and transferred to M/s. Pharmanza Herbal Pvt. Ltd., Gujarat during 8-12th Jan. 2018 at CSIR-CDRI, Lucknow.

CSIR-Central Drug Research Institute, Lucknow
Technology of the product-Novel Osteo-inductive Agent CDRI S008-399 as Medicated Bone implant Material for Fracture Healing transferred to M/s. Ortho Regenics Pvt. Ltd., Hyderabad, on 26 September 2018 during 76th CSIR Foundation Day celebrations
Reunion launched for marketing on 17 February 2016 for rapid fracture healing & post-menopausal osteoporosis

CSIR-Central Drug Research Institute, Lucknow
नवभारत टाइम्स

शोषण की पत्नियों से जुड़े गूंगो दूटी हड़डी

मार्च तक मार्केट में आएगी ददा

लीला असोक कुमार दास को अब वर्ष 2023 तक ददा का विश्वसन बनाना है। ददा की नवीनताओं से ही ददा की समस्याओं का समाधान होगा। ददा की नवीनताओं से ही ददा का संबंध बनाना है। ददा की नवीनताओं से ही ददा का संबंध बनाना है।

CSIR-Central Drug Research Institute, Lucknow

CSIR-Central Drug Research Institute, Lucknow
CDRI makes drug from 'sheesham' leaves for bones

THE TIMES OF INDIA

Bone health drug from leaves of Sheesham

CSIR-Central Drug Research Institute, Lucknow
MoU Signed with NIPER Guwahati

CSIR-Central Drug Research Institute, Lucknow
Agreement executed with CIPLA Limited, Mumbai

CSIR-Central Drug Research Institute, Lucknow
MoU executed with Ministry of Earth Sciences (MoES), Government of India, New Delhi

CSIR-Central Drug Research Institute, Lucknow
MoU executed with DST, New Delhi, DRILS Hyderabad, DRL Hyderabad

CSIR-Central Drug Research Institute, Lucknow
MoU executed with ERA University, Lucknow

CSIR-Central Drug Research Institute, Lucknow
MoU executed with National Institute of Pharmaceutical Education & Research (NIPER), Mohali

CSIR-Central Drug Research Institute, Lucknow
MoU executed with Foundation for Environment and Economic Development Services (FEEDS), Manipur

CSIR-Central Drug Research Institute, Lucknow